VICKI FRYE: Open Payments
NPI 1942271093 · CLEVELAND, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,271 in 108 payments from 23 companies in 2025. Trend: 2023 $1,658 · 2024 $2,096 · 2025 $2,271
Food & beverage: $2,231Long term medical supply or device loan: $40
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $435 |
| ABBVIE INC. | 16 | $344 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $260 |
| Abbott Laboratories | 8 | $165 |
| AstraZeneca Pharmaceuticals LP | 2 | $137 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| PFIZER INC. | 7 | $108 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $78 |
Products named: VRAYLAR, CAPLYTA, Rybelsus, Ozempic, FREESTYLE LIBRE 3, FARXIGA, Auvelity, Kerendia.
Industry payments across TN — which companies pay providers there.
